Paul Daniel Regan Net Worth & Insider Trades
Paul Daniel Regan - Chief Commercial Officer, Intercept Pharmaceuticals Inc
What is Paul Daniel Regan's Net Worth?
The current estimated net worth of Intercept Pharmaceuticals Inc's Chief Commercial Officer, Paul Daniel Regan, is estimated to be about $13.36M . Paul Daniel Regan owns about 1,264 units of Intercept Pharmaceuticals Inc common stock. In the last 2 years at Intercept Pharmaceuticals Inc, Paul Daniel Regan has sold an estimated value of $13.35M worth.
What is Paul Daniel Regan's Past Insider Trading?
Paul Daniel Regan's largest purchase order was 20,000 units , worth over $753.8K on March 7, 2014. Paul Daniel Regan's largest sale order was 20,000 units , worth over $8.69M on March 7, 2014. In total, Paul Daniel Regan has made about 7 transactions over 2 years of their time at Intercept Pharmaceuticals Inc. Paul Daniel Regan usually trades in March, with the busiest year in 2014. The most recent transaction was a sale order of 9,847 units , worth over $1.98M on February 3, 2015.
Paul Daniel Regan
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Paul Daniel Regan's' Mailing Address?
- Mailing address is C/o Intercept Pharmaceuticals, Inc. 18 Desbrosses St. New York NY 10013 NY
Intercept Pharmaceuticals Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| Mark Pruzanski, M.D., | 2020 | $757,850 | - | $4,113,504 | $1,015,996 | $531,995 | $7,660 | $6,427,005 |
| Mark Pruzanski, M.D., | 2019 | $734,292 | - | $4,197,742 | $1,116,118 | $560,265 | $7,368 | $6,615,785 |
| Mark Pruzanski, M.D., | 2018 | $702,000 | - | $1,667,718 | $1,705,358 | $442,260 | $8,623 | $4,525,960 |
| Jerome Durso, | 2020 | $599,524 | - | $2,057,016 | $998,776 | $231,737 | $21,910 | $3,908,963 |
| Jerome Durso, | 2019 | $573,250 | - | $2,089,570 | $1,238,321 | $359,284 | $21,368 | $4,281,793 |
| Jerome Durso, | 2018 | $540,800 | - | $1,554,326 | $775,844 | $292,032 | $22,403 | $3,185,406 |
| Sandip Kapadia, | 2020 | $476,863 | - | $1,087,836 | $528,088 | $184,039 | $21,910 | $2,298,736 |
| Sandip Kapadia, | 2019 | $464,100 | - | $1,001,664 | $586,573 | $252,935 | $21,368 | $2,326,640 |
| Sandip Kapadia, | 2018 | $442,000 | - | $790,164 | $393,544 | $228,735 | $22,403 | $1,876,846 |
| Richard Kim, | 2020 | $456,095 | - | $1,044,360 | $505,128 | $168,056 | $79,211 | $2,252,850 |
| Richard Kim, | 2019 | $442,900 | $202,800 | $890,368 | $521,398 | $265,519 | $76,343 | $2,399,328 |
| Lisa Bright, | 2020 | $480,552 | - | $925,704 | $453,467 | $240,955 | $139,106 | $2,239,784 |
| Ryan Sullivan, | 2020 | $437,107 | - | $1,087,836 | $528,088 | - | $89,942 | $2,142,973 |
| Ryan Sullivan, | 2019 | $445,520 | - | $1,471,902 | $871,713 | $267,089 | $21,368 | $3,077,592 |
| Ryan Sullivan, | 2018 | $376,158 | - | $1,239,112 | $1,190,351 | $229,122 | $173,437 | $3,208,180 |
| Christian Weyer, M.D., M.A.S., | 2020 | $486,731 | - | $925,704 | $453,467 | $170,804 | $21,910 | $2,058,616 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1270073/000110465921055639/tm218121-2_def14a.htm
What are Intercept Pharmaceuticals Inc's Past Insider Trades?
Intercept Pharmaceuticals Inc's most recent insider trade came on March 12, 2021 by Srinivas Akkaraju who bought 237,000 units worth $5.02M . In the last 9 years, insiders at Intercept Pharmaceuticals Inc have sold an estimated value of $1.66B and bought an estimated value of $148.73M worth of shares. Insider trading is most common in January, with the busiest year in 2019. The most active traders at the company are David Shapiro, Chief Medical Officer, Mark Pruzanski, Director, and Lisa Bright, President .
INTERCEPT PHARMACEUTICALS, INC. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||